PDCD1 and neoplasm: An engineered vaccine virus expressing GM-CSF and a PD-L1 inhibitor activates neoantigen-specific T cells, demonstrating enhanced anti-tumor activities, especially in cases resistant to PD-1/PD-L1 blockade therapy [40].